New calcification inhibitors to prevent calcifications in chronic kidney disease
Our project aims to identify novel calcification inhibitors (CIs) to reduce the quantity and pathological properties of calcium-protein-particles (CPP2) to prevent progression of calcifications of cardiovascular tissues, thereby ultimately improving patient- centered outcomes in chronic kidney disease (CKD).
Traditional concepts in CKD generally have failed to foster major breakthrough in treatments leading to improved patient-centred outcome. Recent studies have shown that in CKD, the composition of CPPs undergoes significant changes, becoming denser and promoting inflammation, oxidative stress, and vascular calcification. Our research emphasizes mechanistic views that both the quantity and quality of CPPs dictate their harmful effects on blood vessels. Despite this emerging understanding, there is a lack of mechanistic insights and treatment strategies targeting CPPs. Novel IP6-based calcification inhibitors (CIs) show promise in directly targeting calcification, potentially replacing cumbersome treatments. We integrate innovative treatments, diagnostics, and safe compounds targeting calcification score. Each aspect holds promise for patentable discoveries in a growing market. Success would not only enhance health but also societal engagement, workforce longevity, and reduce healthcare costs. This comprehensive approach not only offers medical advancements but also economic benefits and strategic alliances, fostering innovation in both treatment and diagnostics.
This project employs a dual strategy: test novel CIs to reduce CPP maturation and studying CPP profiles in CKD patients. Furthermore, we will test the short-term effect of CI in a trial among haemodialysis patients on metabolic profile, including markers of inflammation and vasculotoxicity.
The end goal is to identify patient phenotypes that can predict responsiveness to a fixed bolus of CI, offering personalized insights into CI treatment efficacy. This outcome will provide data on CPP metabolism in IP6- treated CKD patients versus a placebo-controlled group. This will allow to investigate the connection between CPP metabolism and IP6-reduced calcification in dialysis patients.
